NCT05712343 is a EARLY_PHASE1 clinical trial of Valacyclovir group in Severe Periodontitis, sponsored by University of California, San Francisco.

Who is sponsoring NCT05712343?

NCT05712343 is sponsored by University of California, San Francisco.

What drugs are being tested in NCT05712343?

Interventions in NCT05712343: Valacyclovir group, Control group.

What condition does NCT05712343 study?

NCT05712343 studies Severe Periodontitis.

Is NCT05712343 still recruiting?

NCT05712343 is currently status unknown. Last updated 12 July 2023.

Last reviewed 2023-07-12 · How we verify

NCT05712343

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Efficacy of Systemic Valacyclovir (Valtrex) on Periodontitis

Status unknown EARLY_PHASE1 Last updated 12 July 2023

What this trial tests

EARLY_PHASE1 trial testing Valacyclovir group in Severe Periodontitis in 40 participants. Status unknown.

Timeline

25 May 2023

Primary endpoint
1 March 2024

1 March 2024

Quick facts

Lead sponsor	University of California, San Francisco
Phase	EARLY_PHASE1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	40
Start date	25 May 2023
Primary completion	1 March 2024
Estimated completion	1 March 2024
Sites	1 location across United States

Drugs / interventions tested

Valacyclovir group
Control group — full drug profile →

Conditions studied

Severe Periodontitis — all drugs for Severe Periodontitis →

Sponsor

University of California, San Francisco

Who can join

Adults 18 to 80, any sex, with Severe Periodontitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The experiment outlined in this proposal is designed to test the hypothesis that herpesvirus suppression by the systemic anti-herpesvirus valacyclovir (Valtrex) can significantly help to arrest the progressive course of severe marginal periodontitis in adult patients. A prospective, randomized, placebo-controlled, double-blind, clinical trial is employed to test this hypothesis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other University of California, San Francisco trials

Trials by the same sponsor.

NCT05284773 — Screening for Acute Malnutrition · NA · withdrawn
NCT04634851 — Video Home Visits for Dietary Counselling · NA · not yet recruiting
NCT06065670 — Assessing Changes in Multi-parametric MRI in Patients With Acute Demyelinating Lesions Taking Clemastine Fumarate as a M · Phase 1, PHASE2 · not yet recruiting
NCT07534098 — Intervention for Hearing Health Among Native Americans · NA · not yet recruiting
NCT06960421 — Exercise-based Frailty Intervention in Lung Transplantation (XFIT) · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05712343 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of California, San Francisco
Last refreshed: 12 July 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05712343.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing